The downgrade from 'Outperform' to 'Neutral' by a prominent analyst, along with a significant reduction in the price target, is likely to negatively impact investor sentiment towards HPP in the short term. This could lead to a decrease in stock price as market participants adjust their expectations based on the new analyst rating and price target.